Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Prestige Consumer
(NYSE:PBH)
Intraday
$70.13
-1.09
[-1.53%]
After-Hours
$70.13
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$70.13
-1.09
[-1.53%]
At close: Apr 24
$70.13
0
[0.00%]
After Hours: 4:00PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Prestige Consumer Stock (NYSE:PBH)
Prestige Consumer Stock (NYSE: PBH)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, March 15, 2024
Earnings Scheduled For March 15, 2024
Benzinga Insights
-
Mar 15, 2024, 5:15AM
Thursday, February 08, 2024
CORRECTION: Prestige Consumer Healthcare Raised 2024 Diluted EPS Guidance To Approximately $4.33 From Prior Guidance Of $4.27-$4.32 Versus Consensus Of $4.32
Benzinga Newsdesk
-
Feb 8, 2024, 11:43AM
Prestige Consumer Healthcare shares are trading higher after the company reported better-than-expected Q3 financial results and raised fiscal 2024 diluted EPS guidance.
Benzinga Newsdesk
-
Feb 8, 2024, 11:43AM
Prestige Consumer Healthcare Reaffirms 2024 Sales Guidance Of $1.135B-$1.14B Versus Consensus Of $1.14B, With Free Cash Flow Of Over $240M
Benzinga Newsdesk
-
Feb 8, 2024, 6:06AM
Prestige Consumer Q3 EPS $1.06 Beats $1.04 Estimate, Sales $282.74M Beat $280.25M Estimate
Benzinga Newsdesk
-
Feb 8, 2024, 6:03AM
Earnings Scheduled For February 8, 2024
Benzinga Insights
-
Feb 8, 2024, 4:43AM
Friday, December 22, 2023
Insight Pharmaceuticals, A Prestige Consumer Healthcare Inc. Company, Issues Voluntary Nationwide Recall Of Americaine 20% Benzocaine Topical Anesthetic Spray Due To The Presence Of Benzene
Benzinga Newsdesk
-
Dec 22, 2023, 9:03AM
Friday, November 24, 2023
Prestige Consumer Healthcare's Subsidiary Insight Pharmaceuticals Issues Voluntary Nationwide Recall Of TING 2% Miconazole Nitrate Athlete's Foot Spray Antifungal Spray Powder Due To The Presence Of Benzene
Benzinga Newsdesk
-
Nov 24, 2023, 8:32AM
Thursday, November 02, 2023
Prestige Consumer Q2 EPS $1.07, Inline, Sales $286.32M Beat $285.21M Estimate
Benzinga Newsdesk
-
Nov 2, 2023, 6:14AM
Earnings Scheduled For November 2, 2023
Benzinga Insights
-
Nov 2, 2023, 4:56AM
Monday, August 14, 2023
Earnings Scheduled For August 14, 2023
Benzinga Insights
-
Aug 14, 2023, 6:45AM
Thursday, August 10, 2023
Chief Executive Officer at Prestige Consumer Exercises Options Worth $2.14M
Benzinga Insights
-
Aug 10, 2023, 11:01AM
Thursday, August 03, 2023
Earnings Scheduled For August 3, 2023
Benzinga Insights
-
Aug 3, 2023, 6:59AM
Prestige Consumer Healthcare Reaffirms FY24 Revenue Outlook Of $1.135B-$1.14B Vs. Consensus Of $1.03B, With EPS Of $4.27-$4.32 Vs. Consensus Of $3.92
Benzinga Newsdesk
-
Aug 3, 2023, 6:29AM
Prestige Consumer Q1 EPS $1.06 Beats $1.01 Estimate, Sales $279.31M Beat $278.07M Estimate
Benzinga Newsdesk
-
Aug 3, 2023, 6:27AM
Monday, June 26, 2023
DA Davidson Reiterates Neutral on Prestige Consumer, Maintains $60 Price Target
Benzinga Newsdesk
-
Jun 26, 2023, 11:53AM
Monday, June 05, 2023
Costco Back To Top Pick Status At Oppenheimer Amidst Positive Retail Projections
Shivani Kumaresan
-
Jun 5, 2023, 1:59PM
Thursday, May 25, 2023
Prestige Consumer's Return On Capital Employed Overview
Benzinga Insights
-
May 25, 2023, 10:46AM
Monday, May 15, 2023
Earnings Scheduled For May 15, 2023
Benzinga Insights
-
May 15, 2023, 5:32AM
Monday, May 08, 2023
DA Davidson Reiterates Neutral on Prestige Consumer, Maintains $60 Price Target
Benzinga Newsdesk
-
May 8, 2023, 4:16AM
Thursday, May 04, 2023
Earnings Scheduled For May 4, 2023
Benzinga Insights
-
May 4, 2023, 6:34AM
Recap: Prestige Consumer Q4 Earnings
Benzinga Insights
-
May 4, 2023, 6:10AM
Prestige Consumer Healthcare Expects FY24 Revenue Of $1.135B-$1.14B (Consensus $1.15B), EPS Of $4.27-$4.32 (Consensus $4.40)
Benzinga Newsdesk
-
May 4, 2023, 6:09AM
Prestige Consumer Q4 Adj EPS $1.07 Beats $1.04 Estimate, Sales $285.90M Beat $279.00M Estimate
Benzinga Newsdesk
-
May 4, 2023, 6:01AM
Wednesday, May 03, 2023
Earnings Preview For Prestige Consumer
Benzinga Insights
-
May 3, 2023, 2:01PM
Friday, March 17, 2023
Looking Into Prestige Consumer's Return On Invested Capital
Benzinga Insights
-
Mar 17, 2023, 10:48AM
RBC Capital Maintains Sector Perform on Prestige Consumer, Lowers Price Target to $104
Benzinga Newsdesk
-
Mar 17, 2023, 8:56AM
Thursday, March 16, 2023
Earnings Scheduled For March 16, 2023
Benzinga Insights
-
Mar 16, 2023, 6:59AM
Friday, February 17, 2023
Oppenheimer Maintains Outperform on Prestige Consumer, Lowers Price Target to $71
Benzinga Newsdesk
-
Feb 17, 2023, 9:47AM
Friday, February 03, 2023
Prestige Consumer's Return On Capital Employed Insights
Benzinga Insights
-
Feb 3, 2023, 9:48AM
Thursday, February 02, 2023
Prestige Consumer Healthcare shares are trading lower after the company lowered FY23 EPS guidance to below analyst estimates.
Michael Horton
-
Feb 2, 2023, 10:22AM
Prestige Consumer Healthcare Narrows FY23 EPS Outlook To $4.18 ($4.18 - $4.20 Prior) Vs. $4.20 Estimate; Free Cash Flow Outlook Of $220M
Benzinga Newsdesk
-
Feb 2, 2023, 6:10AM
Prestige Consumer Healthcare FY23 Revenue Outlook $1.120B - $1.122B Vs. $1.12B Estimate
Benzinga Newsdesk
-
Feb 2, 2023, 6:08AM
Prestige Consumer Q3 EPS $1.04 Beats $1.01 Estimate, Sales $275.52M Beat $273.72M Estimate
Benzinga Newsdesk
-
Feb 2, 2023, 6:05AM
Friday, January 13, 2023
Oppenheimer Maintains Outperform on Prestige Consumer, Raises Price Target to $72
Benzinga Newsdesk
-
Jan 13, 2023, 9:41AM
Thursday, November 24, 2022
Looking Into Prestige Consumer's Return On Capital Employed
Benzinga Insights
-
Nov 24, 2022, 9:46AM
Tuesday, November 22, 2022
Prestige Consumer Insider Trades Send a Signal
Benzinga Insights
-
Nov 22, 2022, 10:06AM
Friday, November 18, 2022
Prestige Consumer's Return On Capital Employed Insights
Benzinga Insights
-
Nov 18, 2022, 9:48AM
Thursday, November 17, 2022
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
Benzinga Insights
-
Nov 17, 2022, 10:13AM
Canaccord Genuity Initiates Coverage On Prestige Consumer with Buy Rating, Announces Price Target of $71
Benzinga Newsdesk
-
Nov 17, 2022, 6:06AM
Thursday, November 03, 2022
Recap: Prestige Consumer Q2 Earnings
Benzinga Insights
-
Nov 3, 2022, 11:47AM
Prestige Consumer: Q2 Earnings Insights
Benzinga Insights
-
Nov 3, 2022, 6:48AM
Prestige Consumer Reaffirms FY23 Sales Guidance Of $1.12B-$1.13B Vs. Consensus of $1.12B. EPS of $4.18-$4.23
Benzinga Newsdesk
-
Nov 3, 2022, 6:07AM
Prestige Consumer Q2 EPS $1.02 Beats $1.00 Estimate, Sales $289.30M Beat $283.19M Estimate
Benzinga Newsdesk
-
Nov 3, 2022, 6:03AM
Earnings Scheduled For November 3, 2022
Benzinga Insights
-
Nov 3, 2022, 5:42AM
Wednesday, September 28, 2022
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Sep 28, 2022, 12:40PM
Tuesday, September 27, 2022
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Sep 27, 2022, 12:42PM
Tuesday, August 30, 2022
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Aug 30, 2022, 12:34PM
Monday, August 29, 2022
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Aug 29, 2022, 11:50AM
Friday, August 26, 2022
Prestige Consumer's Return on Invested Capital Overview
Benzinga Insights
-
Aug 26, 2022, 10:34AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch